IVF\ICSI Outcome in Women With Polycystic Ovary Syndrome
1 other identifier
interventional
156
1 country
1
Brief Summary
Polycystic ovarian syndrome (PCOS) occurs in 5% to 10% of all women of reproductive age and 50% of women who present with sub-fertility due to anovulatory infertility . Clear diagnostic criteria for this condition were identified at the consensus meeting of the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 23, 2023
CompletedFirst Posted
Study publicly available on registry
March 6, 2023
CompletedStudy Start
First participant enrolled
June 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 15, 2026
October 19, 2023
October 1, 2023
3.5 years
February 23, 2023
October 17, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
pregnancy rate
To compare the pregnancy rate at IVF / ICSI cycles between women with PCOS and non PCOS women
From baseline to 15 days after the embryo transfere day.
Study Arms (2)
PCOs Patients
ACTIVE COMPARATORTo compare the pregnancy rate at IVF / ICSI cycles in patients with PCOs
Non PCOs Patients
ACTIVE COMPARATORTo compare the pregnancy rate at IVF / ICSI cycles in patients with without PCOs
Interventions
To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
Eligibility Criteria
You may qualify if:
- Oligo-ovulation or anovulation.
- Clinical and/or biochemical hyper androgenesim.
- Polycystic ovaries.
You may not qualify if:
- Androgen-secreting tumors (ovarian or adrenal).
- Adult-onset congenital adrenal hyperplasia.
- Thyroid diseases.
- Cushing's syndrome.
- Diabetes Mellitus.
- recurrent ICSI failure
- endocrine, hematologic and autoimmune disorders
- Non chromosomal and genetic abnormalities
- Major uterine anomalies, bad surgical history, sever endometriosis, , hydrosalpinx, uterine fibroids
- Azospermia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Egymedicalpedialead
Study Sites (1)
Assuit University hospitals
Asyut, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Momen Kamel, Professor
Assiut University, Faculty of medicine, Assuit.
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 23, 2023
First Posted
March 6, 2023
Study Start
June 1, 2023
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 15, 2026
Last Updated
October 19, 2023
Record last verified: 2023-10
Data Sharing
- IPD Sharing
- Will not share